Table 7 Drug-Related Adverse Events that Occurred in ≥ 3% of Patients (mITT Population), Number of Patients (%)
From: Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
Body System | Tigecycline | Levofloxacin | Total | Fisher Exact | |||
|---|---|---|---|---|---|---|---|
Adverse Event | (N = 216) n (%) | (N = 212) n (%) | (N = 428) n (%) | P-Value | |||
Any adverse event | 96 | 44.4 | 62 | 29.2 | 158 | 36.9 | 0.001* |
Body as a whole | 10 | 4.6 | 10 | 4.7 | 20 | 4.7 | 1.000 |
Cardiovascular system | 9 | 4.2 | 5 | 2.4 | 14 | 3.3 | 0.416 |
Digestive system | 70 | 32.4 | 34 | 16.0 | 104 | 24.3 | <0.001* |
   Diarrhoea | 15 | 6.9 | 14 | 6.6 | 29 | 6.8 | 1.000 |
   Nausea | 54 | 25.0 | 16 | 7.5 | 70 | 16.4 | <0.001* |
   Vomiting | 31 | 14.4 | 10 | 4.7 | 41 | 9.6 | <0.001* |
Haemic and lymphatic system | 7 | 3.2 | 4 | 1.9 | 11 | 2.6 | 0.544 |
Metabolic and nutritional | 15 | 6.9 | 16 | 7.5 | 31 | 7.2 | 0.854 |